Ocular Therapeutix (NASDAQ:OCUL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Rating) in a report released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

OCUL has been the subject of several other research reports. HC Wainwright restated a buy rating and issued a $11.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 7th. JMP Securities dropped their target price on Ocular Therapeutix from $12.00 to $11.00 and set a market outperform rating on the stock in a research report on Tuesday, March 7th.

Ocular Therapeutix Stock Performance

OCUL opened at $4.96 on Thursday. The company has a debt-to-equity ratio of 1.53, a current ratio of 4.13 and a quick ratio of 4.07. The business’s fifty day simple moving average is $4.82 and its 200-day simple moving average is $4.18. Ocular Therapeutix has a 12-month low of $2.57 and a 12-month high of $6.53.

Insider Buying and Selling

In other Ocular Therapeutix news, General Counsel Philip C. Strassburger sold 6,181 shares of the stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $4.24, for a total value of $26,207.44. Following the completion of the sale, the general counsel now directly owns 109,071 shares in the company, valued at $462,461.04. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Ocular Therapeutix news, General Counsel Philip C. Strassburger sold 6,181 shares of the business’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $4.24, for a total transaction of $26,207.44. Following the sale, the general counsel now owns 109,071 shares of the company’s stock, valued at approximately $462,461.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Antony C. Mattessich sold 19,669 shares of the company’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $4.24, for a total transaction of $83,396.56. Following the transaction, the chief executive officer now owns 446,281 shares in the company, valued at approximately $1,892,231.44. The disclosure for this sale can be found here. Insiders have sold a total of 38,155 shares of company stock worth $161,777 in the last ninety days. 3.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Ocular Therapeutix

Several hedge funds and other institutional investors have recently bought and sold shares of OCUL. Federated Hermes Inc. purchased a new stake in shares of Ocular Therapeutix in the 1st quarter valued at $3,080,000. Marshall Wace LLP purchased a new stake in Ocular Therapeutix in the third quarter valued at $2,207,000. Renaissance Technologies LLC grew its position in Ocular Therapeutix by 537.7% during the 1st quarter. Renaissance Technologies LLC now owns 510,805 shares of the biopharmaceutical company’s stock worth $2,528,000 after purchasing an additional 430,705 shares during the period. Barclays PLC grew its position in Ocular Therapeutix by 9,659.2% during the 4th quarter. Barclays PLC now owns 318,834 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 315,567 shares during the period. Finally, UBS Group AG raised its stake in shares of Ocular Therapeutix by 881.0% during the 2nd quarter. UBS Group AG now owns 342,228 shares of the biopharmaceutical company’s stock valued at $1,376,000 after buying an additional 307,344 shares during the last quarter. Institutional investors and hedge funds own 55.40% of the company’s stock.

About Ocular Therapeutix

(Get Rating)

Ocular Therapeutix, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.